Home › Funds › Paradigm Biocapital Advisors LP › EWTX

Paradigm Biocapital Advisors LP position in EWTX

EDGEWISE THERAPEUTICS INC · Health Care

Paradigm Biocapital Advisors LP reported holding 10,778,665 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$437.6M, representing 8.70% of its reported portfolio and ranking #3 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed EWTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)10.78M sh
Reported value held$437.61M
Portfolio Weight8.70%
First reportedQ1 2024
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's EWTX position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in EWTX in Q1 2024 at 2,446,373 shares (US$44.6M). The position peaked in Q3 2026 at 10,778,665 shares, worth US$437.6M. Across 11 filings, Paradigm Biocapital Advisors LP increased the stake 7 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 10,778,665 shares valued at US$437.6M — an increase of 563,210 shares quarter over quarter.. Notable position changes include a 61% increase in Q4 2024 (shares fell 18% over the following quarter), a 89% trim in Q1 2025 (shares fell 40% over the following quarter), a 1128% increase in Q2 2025 (shares rose 24% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 2.45M $44.62M New
Q2 2024 2.33M $41.88M Reduce
Q3 2024 2.79M $74.44M Add
Q4 2024 4.49M $119.99M Add
Q1 2025 500.00K $11.00M Reduce
Q2 2025 6.14M $80.53M Add
Q3 2025 6.17M $100.08M Hold
Q4 2025 6.54M $162.32M Add
Q1 2026 7.37M $232.00M Add
Q2 2026 10.22M $415.05M Add
Q3 2026 10.78M $437.61M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EWTX and 13F data

EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 42 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M), Novo Holdings A/S (US$217.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EWTX

All EWTX fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held EWTX?

Paradigm Biocapital Advisors LP has disclosed EWTX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is Paradigm Biocapital Advisors LP's current position in EWTX?

As of Q3 2026, Paradigm Biocapital Advisors LP holds 10.78M shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $437.61M, representing 8.70% of its reported portfolio and ranking #3.

Has Paradigm Biocapital Advisors LP been buying or selling EWTX?

In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in EWTX. The position peaked in Q3 2026 at 10.78M shares.

Which other funds hold EWTX?

Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Novo Holdings A/S, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.